Following the announcement yesterday that Sanofi (SNY) intends to sell the majority of its Regeneron Pharmaceuticals (REGN) stake, RBC Capital analyst Kennen Mackay told investors that BioMarin’s (BMRN) rare-disease and gene therapy platform is among the “most intriguing potential targets” for the former. Meanwhile, his peer… To see the rest of the story go to thefly.com. (See Story Here):(https://www.thefly.com/permalinks/entry.php/id3100689/-RBC-and-Citi-sees-BioMarin-as-possible-target-but-differ-on-potential-buyer)